The role of molecular genetic analysis within the diagnostic haemato‐oncology laboratory

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Journal of Laboratory Hematology

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1751-553X.2011.01364.xPMID 21883966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAF mutations in hairy-cell leukemia.

  2011cited by this paper
• Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

  2010cited by this paper
• Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements.

  2010cited by this paper
• Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.

  2010cited by this paper
• Guideline for investigation and management of adults and children presenting with a thrombocytosis

  2010cited by this paper
• A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.

  2010cited by this paper
• Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

  2010cited by this paper
• Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

  2010cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis

  2009cited by this paper
• PCR-based methods for the enrichment of minority alleles and mutations.

  2009cited by this paper
• Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

  2009cited by this paper
• Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.

  2009cited by this paper
• Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.

  2009cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009influential reference
• Next-generation sequencing: from basic research to diagnostics.

  2009cited by this paper
• Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.

  2008cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia.

  2008cited by this paper
• Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

  2008cited by this paper
• Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

  2008cited by this paper
• Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008influential reference
• Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis

  2008cited by this paper
• A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

  2008cited by this paper
• High resolution melting for mutation scanning of TP53 exons 5–8

  2007cited by this paper
• Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis

  2007cited by this paper
• Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

  2007cited by this paper
• Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms

  2007cited by this paper
• Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

  2007cited by this paper
• Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  2007cited by this paper
• Evaluation of JAK2V617F in B and T Cell Neoplasms: Identification of JAK2V617F Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals

  2007cited by this paper
• A practical strategy for the routine use of BIOMED‐2 PCR assays for detection of B‐ and T‐cell clonality in diagnostic haematopathology

  2007influential reference
• Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

  2007cited by this paper
• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

  2007cited by this paper
• Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia.

  2006cited by this paper
• Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

  2006cited by this paper
• The RSD code: proposal for a nomenclature of allelic configurations in STR-PCR-based chimerism testing after allogeneic stem cell transplantation

  2006cited by this paper
• Pyrosequencing: history, biochemistry and future.

  2006cited by this paper
• KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

  2006cited by this paper
• Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms

  2005cited by this paper
• Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia

  2005cited by this paper
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

  2005cited by this paper
• Prognostically useful gene-expression profiles in acute myeloid leukemia.

  2004cited by this paper
• Prospective application of a multiplex reverse transcription‐polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single‐laboratory study of 390 paediatric and adult patients

  2004cited by this paper
• Quantification of donor and recipient hemopoietic cells by real-time PCR of single-nucleotide polymorphisms

  2004cited by this paper
• Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

  2004cited by this paper
• Evaluation of STR informativity for chimerism testing – comparative analysis of 27 STR systems in 203 matched related donor recipient pairs

  2004cited by this paper
• Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

  2004cited by this paper
• Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease – a study within the Europe Against Cancer Program

  2004cited by this paper
• High-resolution melting analysis for detection of internal tandem duplications.

  2004cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003influential reference
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms

  2003cited by this paper
• One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

  2003cited by this paper
• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Section 9. t(14;18) with BCL2-IGH rearrangement.

  2003cited by this paper
• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  2003cited by this paper
• Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction.

  2002cited by this paper
• Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization

  2002cited by this paper
• Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations

  2001influential reference
• Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

  2001cited by this paper
• Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection

  1999cited by this paper
• Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.

  1999cited by this paper

• Application of Next-Generation Sequencing to Realize Principles of Precision Therapy in Management of Cancer Patients.

  2025cites this paper
• Educational no. 4: PCR-based methods

  2018cites this paper
• Genomic microarray technologies for the cytogenetics laboratory

  2017cites this paper
• Current Role of Genetics in Hematologic Malignancies

  2016cites this paper
• A new general model for predicting melting thermodynamics of complementary and mismatched B-form duplexes containing locked nucleic acids: application to probe design for digital PCR detection of somatic mutations.

  2015cites this paper
• Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

  2013cites this paper